TG-4010

N/A

Report date: 2022/11/25 16:34:12

Base Information

Drug NameTG-4010
Drug Alias NameTG4010 MUC-1 targeted immunotherapyVV-MUC-IL2TG-4010
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionMucin-1 stimulantsInterleukin-2 stimulants
TargetsMucin-1Interleukin-2
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTransgene Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTransgene SaNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A